Post herpetic neuralgia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:15:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Post herpetic neuralgia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of aneratrigine mesilate (iN1011-N17-02) to find the best dose for treating pain in adults with post-herpetic neuralgia https://clinicaltrials.eu/trial/study-of-aneratrigine-mesilate-in1011-n17-02-to-find-the-best-dose-for-treating-pain-in-adults-with-post-herpetic-neuralgia/ Wed, 29 Apr 2026 15:06:38 +0000 https://clinicaltrials.eu/trial/study-of-aneratrigine-mesilate-in1011-n17-02-to-find-the-best-dose-for-treating-pain-in-adults-with-post-herpetic-neuralgia/ This clinical trial aims to find the optimal dose of iN1011-N17-02 for treating pain in patients with Post-herpetic Neuralgia, a condition where pain persists for at least 3 months after a herpes zoster rash. The study will test different doses of the investigational medication iN1011-N17-02, which contains the active substance aneratrigine mesilate.

The study will compare iN1011-N17-02 with placebo, and patients may also receive other pain medications including paracetamol and tramadol hydrochloride as needed. The medications will be taken orally in the form of capsules or tablets. The treatment period will last for 4 weeks, during which patients will need to regularly rate their pain levels.

Throughout the study, researchers will monitor how well the medication works in reducing pain. They will also track any side effects and measure how the medication is processed by the body. Patients will complete various questionnaires about their pain experience and how it affects their daily activities and sleep. Blood and urine samples will be collected to understand how the medication moves through the body.

]]>